Fig. 7: Patients with a sensitive zAvatar-test have longer Progression-Free Survival.
From: Zebrafish Avatar-test forecasts clinical response to chemotherapy in patients with colorectal cancer
a Kaplan–Meier survival curves were performed comparing the PFS of patients based on sensitivity or resistance of their zAvatar-test (taking into account the tree decision model). The PFS was calculated from the initiation of chemotherapy until either last observation or date of progression. b When analyzing patients from all stages, the zAvatar sensitive group had a longer mean PFS of 30.9 months compared to 7.5 months for the resistant group (N = 55 patients; p < 0.0001). c, d Similarly, in stage II/III patients the mean PFS was 37.0 months versus 11.3 months (N = 32 patients; p < 0.0001), and in stage IV patients the mean PFS was 11.4 months versus 5.9 months (N = 23 patients; p = 0.0063). Source data are provided as a Source Data file.
